ADELIS Technologies’ Post

See how #Medidata and #EORTC are working together to enhance the oncology trial patient experience and unlock unparalleled access to clinical data. #ESMO24 #LifeSciences #Medidata

Are we getting closer to liquid biopsies and ctDNA testing supporting earlier detection of cancer? What does the future of AI in precision oncology look like? Check out our highlights below, if you'd like to know more about what was hot at this year's ESMO... #ESMO2024Highlights #PrecicionMedicine #BetterTestingBetterTreatment

We’re looking foward: In less than 7 days, we will attend the ESMO - European Society for Medical Oncology Congress and cannot wait to 𝗽𝗿𝗲𝘀𝗲𝗻𝘁 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗽𝗼𝘀𝘁𝗲𝗿! 🔝 Will you be there too? Then stay tuned for more details about our poster presentation💡. We look forward to meeting our partners and collaborators at #ESMO2024, and to infusing us with the latest insights and updates from the industry. See you at ESMO! #esmo2024 #oncology #cancerresearch

🌟Countdown to ESMO2024 Congress!🌟 Just one day to go until the ESMO2024 Congress kicks off!🇰🇷🇪🇸🇪🇺 The excitement and anticipation are palpable as all prepare to dive into groundbreaking research, innovative treatments, and inspiring discussions. Can't wait to connect with fellow professionals and explore the future of oncology together. See you there! 🚀 #ESMO2024 #Oncology #MedicalResearch #Excitement #Anticipation #CRO #CNRResearch #ClinicalTrials

🛡️ Dive into ADC Safety Profiles with AccrediMix! 🛡️ Our latest module on Antibody-Drug Conjugates (ADCs) in lung cancer is now available. Featuring insights from Prof Dr Johan Vansteenkiste (UZ Leuven), Prof Dr Anne Sibille (CHU Liège), and Prof Dr Lore Decoster (VUB, Brussels), this module covers: ·     Toxicity profiles ·     Clinical case studies ·     Management strategies Register or log in at accredimix.be to access this essential content and stay at the forefront of oncology care! #LungCancer #MedicalEducation #Oncology #ADCs #ClinicalTrials #AccrediMix With the educational support of Daiichi Sankyo and AstraZeneca *This educational content is intended for healthcare professionals.

Oncotarget is a primarily #oncology-focused, #peerreviewed, #openaccess journal. Papers are #published continuously within yearly volumes in their final and complete form, and quickly released to Pubmed. Learn more about the journal ⬇️ https://lnkd.in/et7MeUrz #publishing

WATCH NOW: Unlocking the Power of Modern Therapeutic Regiments for Prostate Cancer. This is an amazing panel discussion from PVI, PeerView Institute for Medical Education, ZERO and the American Society of Clinical Oncology (ASCO).

WATCH NOW: Unlocking the Power of Modern Therapeutic Regiments for Prostate Cancer. This is an amazing panel discussion from PVI, PeerView Institute for Medical Education, ZERO and the American Society of Clinical Oncology (ASCO).

In the journey towards better cancer treatments, patient access to clinical research is key. At Science 37, we're revolutionizing trial participation by placing our patients' needs at the forefront. With nationwide reach, our remote study teams, led by our dedicated oncology Principal Investigator, Dr. Shaalan Beg, bring trials directly to the homes of patients, reducing travel burdens and prioritizing access. In a recent trial, we enabled participation across 49 states through our Virtual Site. Watch the case study video: https://lnkd.in/g7E4Cgvs 🎗️🔬 #NCRM24 #cancerresearch #oncologytrials #oncology #clinicalresearch #clinicaltrials

If you have heard one of Dr. Rick Patt’s presentations before, then you know you don’t want to miss this webinar! Register now! #RadMD #imaging #clinicalresearch #clinicaltrials #cancerresearch